{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T03:04:05Z","timestamp":1785380645952,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.jad.2014.11.013","type":"journal-article","created":{"date-parts":[[2014,11,18]],"date-time":"2014-11-18T05:41:46Z","timestamp":1416289306000},"page":"70-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Assessment of the efficacy and safety of eslicarbazepine acetate in acute mania and prevention of recurrence: Experience from multicentre, double-blind, randomised phase II clinical studies in patients with bipolar disorder I"],"prefix":"10.1016","volume":"174","author":[{"given":"Heinz","family":"Grunze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Kotlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00edlcar","family":"Falc\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patr\u00edcio","family":"Soares-da-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2014.11.013_bib1","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.nurt.2006.10.005","article-title":"Eslicarbazepine acetate (BIA 2-093)","volume":"4","author":"Almeida","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.jad.2014.11.013_bib2","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2000"},{"key":"10.1016\/j.jad.2014.11.013_bib3","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.eplepsyres.2010.01.014","article-title":"Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy","volume":"89","author":"Ben-Menachem","year":"2010","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.jad.2014.11.013_bib4","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/j.1528-1167.2012.03519.x","article-title":"Pharmacokinetics and drug interactions of eslicarbazepine acetate","volume":"53","author":"Bialer","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.jad.2014.11.013_bib5","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1001\/archpsyc.60.4.392","article-title":"A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder","volume":"60","author":"Bowden","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2014.11.013_bib6","series-title":"Bipolar Disorder","first-page":"367","article-title":"Bipolar disorder and safety monitoring for clinicians: a review of the evidence and the implications","author":"Bushe","year":"2010"},{"key":"10.1016\/j.jad.2014.11.013_bib7","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.4088\/JCP.v64n0906","article-title":"A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder","volume":"64","author":"Calabrese","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2014.11.013_bib8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jad.2006.01.032","article-title":"Clinical and therapeutic implications of predominant polarity in bipolar disorder","volume":"93","author":"Colom","year":"2006","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2014.11.013_bib9","unstructured":"Committee for proprietary medicinal products (CPMP), 2001. Note for guidance on clinical investigation of medicinal products for the treatment and prevention of bipolar disorder, London."},{"key":"10.1016\/j.jad.2014.11.013_bib10","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1111\/epi.12242","article-title":"Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers","volume":"54","author":"Elger","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.jad.2014.11.013_bib11","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1528-1167.2008.01946.x","article-title":"Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study","volume":"50","author":"Elger","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.jad.2014.11.013_bib12","unstructured":"EMA, 2009. European Medicines Agency \u2013 Zebinix\u00ae (eslicarbazepine acetate): summary of product characteristics [online]."},{"key":"10.1016\/j.jad.2014.11.013_bib13","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/bdd.549","article-title":"Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2-093), a new voltage-gated sodium channel blocker","volume":"28","author":"Falcao","year":"2007","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.jad.2014.11.013_bib14","unstructured":"FDA, 2013. Food and Drug Administration \u2013 Aptiom\u00ae (eslicarbazepine acetate): Label."},{"issue":"Suppl 1","key":"10.1016\/j.jad.2014.11.013_bib15","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1007\/s00406-012-0323-x","article-title":"Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry","volume":"262","author":"Fountoulakis","year":"2012","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.jad.2014.11.013_bib16","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1176\/appi.ajp.161.2.217","article-title":"Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials","volume":"161","author":"Geddes","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2014.11.013_bib17","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1600-0404.2009.01218.x","article-title":"Efficacy and safety of 800 and 1200mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures","volume":"120","author":"Gil-Nagel","year":"2009","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.jad.2014.11.013_bib18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/15622970902823202","article-title":"The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania","volume":"10","author":"Grunze","year":"2009","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.jad.2014.11.013_bib19","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0165-0327(02)00332-4","article-title":"The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases","volume":"73","author":"Judd","year":"2003","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2014.11.013_bib20","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1399-5618.2010.00836.x","article-title":"Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6)","volume":"12","author":"Licht","year":"2010","journal-title":"Bipolar Disord."},{"issue":"Suppl 2","key":"10.1016\/j.jad.2014.11.013_bib21","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1111\/j.1399-5618.2012.00989.x","article-title":"Balanced efficacy, safety, and tolerability recommendations for the clinical management of bipolar disorder","volume":"14","author":"Malhi","year":"2012","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2014.11.013_bib22","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/archpsyc.64.5.543","article-title":"Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication","volume":"64","author":"Merikangas","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2014.11.013_bib23","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archgenpsychiatry.2011.12","article-title":"Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative","volume":"68","author":"Merikangas","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2014.11.013_bib24","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2014.11.013_bib25","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0140-6736(02)07450-0","article-title":"Bipolar disorder","volume":"359","author":"Muller-Oerlinghausen","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jad.2014.11.013_bib26","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1528-1167.2012.03595.x","article-title":"Steady-state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers","volume":"54","author":"Nunes","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.jad.2014.11.013_bib27","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.eplepsyres.2011.05.013","article-title":"Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures","volume":"96","author":"Perucca","year":"2011","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.jad.2014.11.013_bib28","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0165-1781(97)00123-6","article-title":"Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP","volume":"73","author":"Spearing","year":"1997","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jad.2014.11.013_bib29","unstructured":"Sperling, M., Harvey, J., Biraben, A., Galimberti, C., Kowacs, P., Hong, S.B., Cheng, H., Blum, D., Nunes, T., Soares-da-Silva, P., 2013. Adjunctive eslicarbazepine acetate in patients with refractory partial-onset seizures: efficacy results of a 12 week randomized placebo-controlled study. In: Proceedings of the 67th Annual Meeting of the American Epilepsy Society, Washington, D.C., p. 65, (abstract 63.210)."},{"key":"10.1016\/j.jad.2014.11.013_bib30","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1185\/030079905X46340","article-title":"Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies","volume":"21","author":"Vieta","year":"2005","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jad.2014.11.013_bib31","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1001\/jama.1996.03540040037030","article-title":"Cross-national epidemiology of major depression and bipolar disorder","volume":"276","author":"Weissman","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.jad.2014.11.013_bib32","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/npp.2010.192","article-title":"Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials","volume":"36","author":"Yildiz","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2014.11.013_bib33","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity and sensitivity","volume":"133","author":"Young","year":"1978","journal-title":"Br. J. Psychiatry"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016503271400723X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016503271400723X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T01:14:23Z","timestamp":1759022063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016503271400723X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":33,"alternative-id":["S016503271400723X"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2014.11.013","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of the efficacy and safety of eslicarbazepine acetate in acute mania and prevention of recurrence: Experience from multicentre, double-blind, randomised phase II clinical studies in patients with bipolar disorder I","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2014.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}